A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem-Reference-Cited by-同舟云学术

A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem

Published:2001-10 Issue:1-2 Volume:228 Page:5-17
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Singh Saranjit,Mariappan T.T,Shankar R,Sarda N,Singh Baljinder

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference27 articles.

1. Human bioavailabilty studies;Acocella;Bull. Int. Union Tuberc. Lung Dis.,1989

2. Anonymous, 1999. Panel discussions I, II and III. Int. J. Tuberc. Lung Dis. 3, S317–S321, S351–S352, S381–S387.

3. Availability of quality fixed dose combinations for the treatment of TB: what can we learn from studying the World Health Organization's vaccine model;Blomberg;Int. J. Tuberc. Lung Dis.,1999

4. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid;Boman;Eur. J. Clin. Pharmacol.,1974

5. Mechanism of inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite;Boman;Eur. J. Clin. Pharmacol.,1975

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicochemical interaction of rifampicin and ritonavir-lopinavir solid dispersion: an in-vitro and ex-vivo investigation;Drug Development and Industrial Pharmacy;2024-02-02

2. Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine;Molecules;2024-01-09

3. Development of a Novel In Vitro Model to Study Lymphatic Uptake of Drugs via Artificial Chylomicrons;Pharmaceutics;2023-10-26

4. New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS;Journal of Pharmaceutical and Biomedical Analysis;2023-10

5. Assessing Polymorphic Purity of Rifampicin in Double and Triple-Drug Fixed-Dose Combination Products;Journal of Pharmaceutical Sciences;2023-09